Genelux Corporation Common Stock (GNLX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Genelux Corporation Common Stock (GNLX) has a cash flow conversion efficiency ratio of -0.264x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.06 Million) by net assets ($22.92 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Genelux Corporation Common Stock for the company's overall valuation and market capitalisation.
Genelux Corporation Common Stock - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Genelux Corporation Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Genelux Corporation Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Genelux Corporation Common Stock ranked by their cash flow conversion efficiency. Explore GNLX operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kino Indonesia Tbk PT
JK:KINO
|
0.132x |
|
Merit Turizm Yatirim ve Isletme AS
IS:MERIT
|
0.006x |
|
Kukbo Design Co. Ltd
KQ:066620
|
0.056x |
|
The Joint Corp
NASDAQ:JYNT
|
0.138x |
|
William Penn Bancorp Inc
NASDAQ:WMPN
|
-0.010x |
|
Tander Inversiones SOCIMI SA
MC:YTAN
|
0.016x |
|
Crest Ventures Limited
NSE:CREST
|
0.013x |
|
Lippo General Insurance Tbk
JK:LPGI
|
0.125x |
Annual Cash Flow Conversion Efficiency for Genelux Corporation Common Stock (2019–2025)
The table below shows the annual cash flow conversion efficiency of Genelux Corporation Common Stock from 2019 to 2025. View GNLX share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $11.54 Million | $-25.27 Million | -2.189x | -170.91% |
| 2024-12-31 | $26.27 Million | $-21.23 Million | -0.808x | +22.40% |
| 2023-12-31 | $19.47 Million | $-20.27 Million | -1.041x | -1143.31% |
| 2022-12-31 | $-35.78 Million | $-3.57 Million | 0.100x | -49.82% |
| 2021-12-31 | $-33.11 Million | $-6.58 Million | 0.199x | -37.47% |
| 2020-12-31 | $-22.66 Million | $-7.21 Million | 0.318x | +9.24% |
| 2019-12-31 | $-24.81 Million | $-7.22 Million | 0.291x | -- |
About Genelux Corporation Common Stock
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a te… Read more